These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34096327)

  • 1. Significantly Lower Immunoglobulin M Levels 6 Months After Disease Onset in Patients With Kawasaki Disease With Coronary Artery Lesions.
    Chang LS; Chen YJ; Huang PY; Chen KD; Lo MH; Huang YH; Guo MM; Kuo HC
    J Am Heart Assoc; 2021 Jun; 10(12):e020505. PubMed ID: 34096327
    [No Abstract]   [Full Text] [Related]  

  • 2. Biomarkers of intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease.
    Kong WX; Ma FY; Fu SL; Wang W; Xie CH; Zhang YY; Gong FQ
    World J Pediatr; 2019 Apr; 15(2):168-175. PubMed ID: 30809758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possible new role of vascular endothelial growth factor-D during the acute phase of Kawasaki disease.
    Hirono K; Ichida F
    Circ J; 2011; 75(6):1324-5. PubMed ID: 21532175
    [No Abstract]   [Full Text] [Related]  

  • 4. Elevated D-dimer level is a risk factor for coronary artery lesions accompanying intravenous immunoglobulin-unresponsive Kawasaki disease.
    Masuzawa Y; Mori M; Hara T; Inaba A; Oba MS; Yokota S
    Ther Apher Dial; 2015 Apr; 19(2):171-7. PubMed ID: 25257673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of lower eosinophil-related T helper 2 (Th2) cytokines with coronary artery lesions in Kawasaki disease.
    Kuo HC; Wang CL; Liang CD; Yu HR; Huang CF; Wang L; Hwang KP; Yang KD
    Pediatr Allergy Immunol; 2009 May; 20(3):266-72. PubMed ID: 19438983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of serum IL6 and CRP levels with respect to coronary changes and treatment response in Kawasaki disease patients: a prospective study.
    Nandi A; Pal P; Basu S
    Rheumatol Int; 2019 Oct; 39(10):1797-1801. PubMed ID: 31302740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of red blood cell distribution width for coronary artery lesions in patients with Kawasaki disease.
    Xu H; Fu S; Wang W; Zhang Q; Hu J; Gao L; Zhu W; Gong F
    Cardiol Young; 2016 Aug; 26(6):1151-7. PubMed ID: 26435202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased production of vascular endothelial growth factor-d and lymphangiogenesis in acute Kawasaki disease.
    Ebata R; Abe J; Yasukawa K; Hamada H; Higashi K; Suwazono Y; Saito H; Terai M; Kohno Y
    Circ J; 2011; 75(6):1455-62. PubMed ID: 21483160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kawasaki syndrome: role of superantigens revisited.
    Leung DYM; Schlievert PM
    FEBS J; 2021 Mar; 288(6):1771-1777. PubMed ID: 32770775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous immunoglobulin plus corticosteroids prevent coronary artery abnormalities in Kawasaki disease.
    Brogan P; Levin M
    Evid Based Med; 2013 Dec; 18(6):217-8. PubMed ID: 23564929
    [No Abstract]   [Full Text] [Related]  

  • 11. [Cytokines in Kawasaki disease].
    Abe J
    Nihon Rinsho; 2014 Sep; 72(9):1548-53. PubMed ID: 25518401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Evaluation of Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio for Intravenous Immunoglobulin Resistance in a Large Cohort of Kawasaki Disease Patients.
    Liu X; Zhou K; Hua Y; Wu M; Liu L; Shao S; Wang C
    Pediatr Infect Dis J; 2020 Mar; 39(3):229-231. PubMed ID: 31917754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kawasaki disease: part II. Complications and treatment.
    Bayers S; Shulman ST; Paller AS
    J Am Acad Dermatol; 2013 Oct; 69(4):513.e1-8; quiz 521-2. PubMed ID: 24034380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asymmetric and symmetric dimethylarginine are associated with coronary artery lesions in Kawasaki disease.
    Huang YH; Tain YL; Lee CP; Kuo HC
    J Pediatr; 2014 Aug; 165(2):295-9. PubMed ID: 24874168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The serum concentration of soluble interleukin-2 receptor in patients with Kawasaki disease.
    Teraura H; Kotani K; Minami T; Takeshima T; Shimooki O; Kajii E
    Ann Clin Biochem; 2017 Mar; 54(2):209-213. PubMed ID: 28081636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphocyte Hydrogen Sulfide Production Predicts Coronary Artery Lesions in Children with Kawasaki Disease: A Preliminary, Single-Center Study.
    Lin J; Zhao H; Jiao F; Ma L; Wang W; Ma L
    J Trop Pediatr; 2020 Apr; 66(2):171-177. PubMed ID: 31302704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DIAGNOSTIC VALUE OF THE REACTION AT THE BACILLUS CALMETTE-GUÉRIN VACCINATION SITE IN KAWASAKI DISEASE.
    Diniz LMO; Castanheira RG; Giampietro YG; Silva MS; Nogueira FD; Pessoa PD; Santos TMDS; Coutinho GS; Romanelli RMC
    Rev Paul Pediatr; 2021; 39():e2019338. PubMed ID: 32876305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased Pentraxin 3 Levels Correlate With IVIG Responsiveness and Coronary Artery Aneurysm Formation in Kawasaki Disease.
    Kitoh T; Ohara T; Muto T; Okumura A; Baba R; Koizumi Y; Yamagishi Y; Mikamo H; Daigo K; Hamakubo T
    Front Immunol; 2021; 12():624802. PubMed ID: 33912155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A machine learning approach to predict intravenous immunoglobulin resistance in Kawasaki disease patients: A study based on a Southeast China population.
    Wang T; Liu G; Lin H
    PLoS One; 2020; 15(8):e0237321. PubMed ID: 32853226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to intravenous immunoglobulin (IVIG) in Kawasaki disease: no influence of different IVIG lot utilisation.
    Pagnini I; Marino A; Simonini G; Cimaz R
    Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S170. PubMed ID: 22410254
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.